Ms. Umi Chong is the Senior Director of Finance and Controller of 858 Therapeutics. Umi started her career in public accounting at Ernst & Young. Prior to joining 858, Umi was an early employee of Syrrx, a structure-based drug discovery company acquired by Takeda in 2005. Umi was responsible for building finance and accounting infrastructure, operations and reporting at Syrrx and led the transition and integration of accounting and finance operations upon acquisition by Takeda. Umi served as the Finance Site Head of Takeda San Diego. Prior to Syrrx/Takeda, Umi held various financial positions in SEC reporting, international consolidations and reporting and mergers and acquisitions.

Umi is a Certified Public Accountant and holds a B.S. in Accounting from Indiana University.